DAY 2: Monday, September 22, 2025
Program subject to change.
07:00 - 18:00
Registration Open
08:30 - 09:30
Plenary Lecture 1
Predicting Altered Drug Disposition in Disease States using Novel In Vitro and Modeling Tools
Kim Brouwer, UNC Chapel Hil, USA
10:00 - 12:00
Concurrent Symposia 1 & 2
Symposium 1: Transporter-Enzyme Interplay & Drug-Drug Interactions in Health & Disease
Co-chairs: Xiaoyan Chu, Merck, USA; Jacqueline Tiley, University of North Carolina at Chapel Hill, USA
-
This session, featuring speakers from academia and industry, will cover topics on 1) the interplay between drug-metabolizing enzymes and transporters that influence drug pharmacokinetics and DDIs, and how physiologically based pharmacokinetic (PBPK) models can support our understanding of these complex processes, and 2) the effect of disease on enzymes and transporters. Attendees will gain insights into this cutting-edge research and will have a better understanding of current methodologies and challenges in predicting pharmacokinetics and DDIs, and how disease can affect drug efficacy and safety.
Transporter-Enzyme Interplay and Drug-Drug Interactions in Hepatic Endoplasmic Reticulum
Yukio Kato, Kanazawa University, Japan
Understanding CYP3A4 and P-gp Mediated Drug-Drug Interactions through PBPK Modeling - Case Example of Pralsetinib
Christine Bowman, Genentech, USACYP2C8 Clinical Probe Substrates and the Significance of OATP1B-CYP Interplay: From Repaglinide to Daprodustat
Manthena Varma, Pfizer, USAAltered Transporter Function in Patients with Autosomal Dominant Polycystic Kidney Disease: Impact on Bile Acids, Coproporphyrin-I, Drug-Drug Interactions, and Drug-Induced Liver Injury
Jacqueline Tiley, UNC, USA
Symposium 2: Oral Delivery of bRo5 Compounds
Co-chairs: Simone Schadt, Roche, Switzerland; Donglu Zhang, Genentech, USA
-
Synopsis: In this session, we will explore the challenges and advancements in enhancing the oral bioavailability of beyond rule of five (bRo5) compounds, such as peptides and degraders. These compounds often exhibit poor permeability and solubility, making oral delivery a significant hurdle. Attendees will gain insights from recent case studies and research findings, highlighting successful examples and ongoing efforts in this critical area of drug development.
Inroads with Gastrointestinal Permeation Enhancers for Oral Peptides
Mridula Dogra, Lilly, USASemaglutide
Stephen Buckley, Nova Nordisk, DenmarkNovel Approaches to deliver PROTACs to the site of action
Donglu Zhang, Genentech/Roche, USANovel strategies to assess and improve oral bioavailability of bRo5 compounds, including degraders and chameleonicity
Ryoichi Saito
12:00 - 15:00
Lunch/Exhibits/Poster Viewing/Supplier Showcase
15:00 - 16:30
Concurrent Symposia 3 & 4
Symposium 3: Nuclear Receptors in Drug Discovery and Development
Co-chairs: Huichang (Nancy) Bi, Southern Medical University, China; Taosheng Chen, St. Jude's Children's Research Hospital, USA
-
The human nuclear receptor (NR) superfamily contains 48 members with diverse roles in physiology and disease. NRs are attractive drug targets. Approved NR-targeting therapies have had immense success treating various diseases. Speakers for this session are experts actively working on various members of the NR superfamily by using multidisciplinary approaches such as biology, pharmacology, medicinal chemistry and structural biology.
Multiple approaches to inhibit the xenobiotic receptor PXR
Taosheng Chen, St. Jude Children's Research Hospital, USA
Novel PXR/CAR modulators in long-term human primary hepatocyte culture
Hongbing Wang, Maryland University, USA
Symposium 4: Protein-based and Novel Modalities
Co-chairs: David Belair, Abbvie, USA; Nita Patel, Eli Lilly, USA
-
This session will highlight the importance of understanding the disposition and behavior of various drugs that use antibodies to facilitate their targeting. Novel modalities such as antibody-drug conjugates, RNA conjugates, or protein degraders will be discussed. The presentations will focus on overcoming ADME challenges of antibody conjugates, mechanistic PKPD modeling of degraders and translational modeling of integrated molecular and ADME kinetics for next-generation ADCs.
Overcoming ADME challenges of Antibody Conjugates (Diversified applications ADC/ARC)
Lukasz Chlewicki, Lilly, USAMechanistic PKPD Modeling for Therapeutic Protein Degraders/ADCs
David Belair, Abbvie, USA
16:45 - 18:15
Debate Session
Motion: This house believes that in silico models, in vitro studies, and artificial intelligence will replace in vivo studies as the primary decision-making tools in the preclinical sciences within the next decade.
Moderator: Andreas Reichel, Bayer, Germany
Robin Haid, Bayer, USA
Kevin Read, University of Dundee, UK
Ben-Filippo Krippendorff, Pierre Fabre Group, France
Steve Hood, GSK, UK